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Abstract 
A major objective in biological research is to understand spatial and temporal requirements for any 
given gene, especially in dynamic processes acting over short time periods, such as catalytically-
driven reactions, subcellular transport, cell division, cell rearrangement and cell migration. The 
interrogation of such processes requires the use of rapid and flexible methods of interfering with gene 
function. However, many of the most widely-used interventional approaches, such as RNAi or Crispr-
CAS9, operate at the level of the gene or its transcripts, meaning that the effects of gene perturbation 
are exhibited over longer time-frames than the process under investigation. There has been much 
activity over the last few years to address this fundamental problem. Here we describe recent 
advances in disruption technologies acting at the level of the expressed protein, involving inducible 
methods of protein cleavage, (in)activation, protein sequestration or degradation. Drawing on 
examples from model organisms we illustrate the utility of fast-acting techniques and discuss how 
different components of the molecular toolkit can be employed to dissect previously intractable 
biochemical processes and cellular behaviours. 
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Introduction 
Genetic manipulation, which operates at the level of the gene or its transcribed product, has proven 
to be indispensable for the identification of molecular components required for biological processes 
and understanding how these components act together to construct functional cells, tissues and 
organisms. There are now a myriad of tools for mutational analysis that have been accumulated for 
over a century, fuelling gene discovery through forward genetic screens and facilitating reverse 
genetics to probe gene function [1-3]. Recent developments, in particular CRISPR-based approaches 
and RNA interference (RNAi), promise to further transform our understanding by facilitating high-
throughput reverse genetics and gene editing with nucleotide-level precision [4, 5]. Gene 
overexpression technologies have also become extremely advanced, featuring a high level of spatial 
and temporal control that has enabled a range of developmentally targeted gain-of-function studies. 
Heterologous gene expression systems, such as yeast GAL4-UAS, have proven to be particularly 
versatile in this regard [6]. Yet, quite often, the genetic tools used to perturb gene function are not 
able to keep pace with dynamic biological events that can act over different timescales from less than 
a second to many hours or days, depending on the process.  
 
Processes acting over short times are particularly recalcitrant to genetic analysis because there is a 
considerable delay between perturbations at the transcriptional or post-transcriptional level and the 
corresponding effect on the encoded protein. Consequently, genetic approaches are typically 
incapable of selectively disrupting the encoded protein of interest at the time when the effects of 
experimental manipulation are measured. This is particularly a problem for analysing the function of 
proteins required at multiple points of the same process. A partial solution to this problem might be to 
monitor the process under investigation in real-time, so as to capture more information about the 
biological effects than can be revealed at a fixed time point [7].  Yet significant limitations remain, 
especially for the analysis of protein function in vivo. For instance, mutation of a gene required for 
development might result in early lethality making later processes impossible to analyse. Alternatively 
in the case of transgenic RNAi, which typically results in partial loss-of-function, it may not be 
possible to drive expression of the transgene early enough for knockdown to occur before the 
process has already taken place. This is particularly a problem early in development, where it can 
take a considerable time for the maternal contribution of RNA and protein to be exhausted. Another 
major consideration is the existence of compensatory homeostatic mechanisms that may circumvent 
the requirement for the protein under investigation. Although this is often a reason cited for lack of 
knockout phenotypes in mice, the underlying mechanisms are frequently not well described. Studies 
employing fast-acting methods have the potential to resolve such issues, as illustrated by a recent 
study of the cell-surface glycoprotein CD44. CD44 isoforms act as coreceptors for the receptor 
tyrosine kinases c-Met and VEGFR-2 but do not produce overt phenotypes when knocked-out in 
mice [8]. Using blocking antibodies, it was shown that acute disruption of CD44v6 inhibited cell 
proliferation and c-Met activation in wild type mice, but that ICAM-1 compensated for the CD44v6 
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isoform in CD44 null mice [8]. This study illustrates that rapid blockade of protein function can be a 
powerful way of resolving problems associated with slow-acting or constitutive methods of gene 
disruption. However, only a minority of proteins are currently open to pharmacological manipulation 
and the development of specific blocking reagents for every protein of interest based on their intrinsic 
properties is a long way away.  
 
A successful strategy that has been adopted by the research community over the last few years to 
increase the range of targets that can be manipulated pharmacologically, has been to take well-
characterised ligand-interaction domains from heterologous systems, and genetically engineer them 
into proteins of interest. In parallel to this chemical genetics approach, researchers have also found 
ways of incorporating domains responsive to other triggers, such as light, temperature and pH. This 
has spawned a new generation of tools that act directly at the level of the expressed protein and 
have the potential to provide insight into acute perturbations, give access to analysis over short times 
and allow reversible switching. Such tools can be broadly categorised according to their mode of 
action: those that, disrupt protein activity through complex (de)formation, (in)activate proteins by 
induced splicing or cleavage, and directly target a protein for degradation through the endogenous 
cell machinery. Here we focus primarily on tools for conditional control of protein function that fall into 
one of these three categories and are fast acting, providing examples of their application as a guide 
to researchers considering their use. 
 
Complex Formation 
The promotion of interactions between proteins of interest represents a powerful strategy for the 
conditional control of protein activity. There are a number of different mechanisms by which such 
interactions can be engineered to spatiotemporally regulate protein activity in response to different 
stimuli, in a way that is both precise and fast acting (Fig. 1, Table 1).   
 
Chemically Induced Dimerisation (CID) 
One of the first mechanisms involving engineered protein complex formation utilised small molecules, 
referred to as chemical inducers of dimerisation (CIDs), which simultaneously bind domains 
engineered into two proteins of interest, bringing them into close proximity and promoting their 
interaction (Fig. 1A, Table 1). Methods involving CIDs can influence protein activity by promoting 
(dis)aggregation, altering transcription or by changing the sub-cellular localisation of target proteins. 
The application of CIDs to control protein activity and study protein function spans the past two 
decades, with the majority of applications utilising naturally occurring CIDs, found to dimerise specific 
protein-ligand pairs [9-11]. For a small molecule to be successful in CID approaches it must have the 
ability to simultaneously bind two proteins, and therefore must have two, high affinity, highly specific 
protein binding domains, joined in a way that allows both target proteins to bind and interact [12].  
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FK1012 
The first, naturally occurring CID, FK1012, was reported in 1993. FK1012 is a derivative of the 
immunosuppressant drug FK506, which was found in 1991 to be capable of binding calcineurin and 
the FK506-binding protein (FKBP12) with high affinity [13]. FK1012 is a synthetic dimer of FK506 that 
lacks the intrinsic biological activity of FK506 and has since been utilised as a CID to bind multiple 
FKBP12 domains [14], bringing target proteins together in a defined, reversible fashion and 
demonstrating the subtleties required for successful CID design [12]. The initial CID concept was 
demonstrated through a system in which addition of FK1012 activated the endogenous T-cell 
signalling cascade, via fusion of FKBP12 to the proximity-regulated -chain of the T-cell receptor 
leading to receptor aggregation and subsequent activation [14]. FK1012 and other CIDs capable of 
dimerising a single protein domain, discovered in the years following, have since been applied to the 
study of many important cellular processes to, for example, induce apoptosis via aggregation of the 
Fas membrane signalling protein [15] or regulate transcription through ligand-dependent 
(dis)association of transcriptional activators with promoter regions [16]. 
 
Rapamycin 
Whilst the first CIDs were only capable of homodimerisation, these approaches could, in theory, be 
used to generate heterodimers if two proteins of interest were tagged with the same domain. The 
result would however be a mixture of heterodimers and homodimers of the two individual proteins of 
interest. The development of methods involving naturally occurring heterodimerisers therefore 
followed, with the most notable heterodimeriser rapamycin dominating the field since its discovery 
[17]. Rapamycin is an immunosuppressant drug that selectively binds both FKBP12 and FKBP-
rapamycin associated protein (FRAP/mTOR) [18]. The FKBP and FRB domains of these proteins, 
respectively, are sufficient for binding and retain the binding affinity of the full-length proteins [19]. A 
key step in the application of rapamycin as a CID was the production of rapamycin derivatives, 
known as “rapalogs”, which have a much lower affinity for endogenous proteins, thereby 
circumventing rapamycin’s immunosuppressive activity. In parallel, the rapamycin-binding regions 
from FKBP12 and mTOR, were remodelled to bind the rapalog at nanomolar affinity, providing an 
orthologous rapamycin system for CID applications [20-22]. These rapalogs have since been used to 
conditionally dimerise proteins to interrogate many different biological processes. Notable examples 
include the study of mitosis, in which rapamycin-induced binding of the endoplasmic reticulum and 
golgi membranes showed that these structures remain segregated during mitosis in mammalian cells 
[23], and also the study of phosphoinositides and their roles in endocytosis and intracellular-
trafficking [24, 25].  
 
One specific application of rapamycin-mediated control in mammalian cells is the knocksideways 
(KS) method (Table 1), which acutely sequesters protein activity through a change in sub-cellular 
localisation. The KS method is capable of rapidly re-routing target proteins containing an FKBP 
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domain to the mitochondria on a timescale of seconds, through rapamycin-induced binding to an 
FRB-containing protein with a mitochondrial targeting signal (Mito-YFP-FRB) (Fig. 1B) [26]. This 
method utilises the principle of mitochondrial re-routing, whereby the protein of interest accumulates 
on the outer mitochondrial membrane in a way that, providing the new localisation is not compatible 
with protein function, sequesters protein activity, but remains tolerable to cells [27]. In an initial proof-
of-principle study the KS method was used to study the role of two subunits of the adaptor protein 
(AP) complexes of clathrin-coated vesicles AP-1 and AP-2 [26]. Robinson and colleagues [26] used 
rapamycin-induced re-routing of AP-1 and AP-2 to the mitochondria, in combination with siRNA 
knockdown of the endogenous protein, to demonstrate the requirement for both proteins in the 
endocytosis pathway. Whilst the phenotype of AP-2 sequestration was similar to that resulting from 
siRNA approaches alone, the corresponding phenotype observed for AP-1 was distinct from that of 
the siRNA knockdown and is accredited to more rapid depletion achieved in the KS approach [26]. 
The effectiveness of the KS approach for rapid changes in protein activity have since been 
demonstrated in a number of varied applications to fast-acting processes in mammalian cells. For 
example, Cheeseman and colleagues [28] used the rapamycin-mediated approach to specifically 
remove TACC3-ch-TOG-clathrin complexes from the mitotic spindle within a timescale of 5 minutes 
following rapamycin addition. By re-routing these complexes to the mitochondria and away from 
mitotic spindles at defined stages in mitosis they were able to deduce their role in maintaining tension 
in kinetochore fibres, which are essential for correct segregation of chromosomes. Again, this 
phenotype was distinct from that observed with siRNA alone, demonstrating the utility of the KS 
approach. 
 
CIDs offer an efficient way to control the dynamics of processes reliant on oligomerisation. However, 
the same principles can also be used for the opposite mode of control, in which processes are 
inhibited by oligomerisation and activated upon addition of a ligand that dissociates the complexes. 
To enable this mode of control, Rollins and colleagues identified an FKBP12 mutant F36M-FKBP 
(FM) with the ability to form discrete dimers that can be dissociated rapidly upon addition of ligand 
[22]. Using these tools, Al-Bassam and colleagues [29] were able to develop a novel pulse-chase 
system in which exogenous FM tagged membrane proteins were accumulated gradually in the ER, 
and sequestered by the formation of aggregates. Within minutes of small molecule ligand addition, 
the FM domins dissociated and the accumulated membrane proteins could be simultaneously 
released for synchronous continuation along the secretory pathway [29]. Through this method, Al-
Bassam and colleagues were able to study proteins in a specific phase of the secretory pathway 
without interference from proteins in other phases of the pathway and thus overcome a major 
problem associated with studying this dynamic process.  
 
In order for CID to be successful, target proteins must be considered on a case-by-case basis and 
prior knowledge of protein function is usually required in order to achieve thorough inactivation. With 
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nanomolar affinities between ligand-protein pairs, CID approaches have high specificity and high 
efficiency. However, this puts them at a disadvantage in terms of reversibility, as they often require 
an additional ligand that competes for binding to relieve protein inactivation/sequestration. Effects are 
often irreversible [30]. Whilst CID approaches were initially developed and demonstrated in vitro, 
these applications have since been developed to allow in vivo studies [31]. However, the requirement 
for exogenous small ligand addition and resulting potential for off-target effects somewhat limit the 
practicality of such applications. Also, although the KS approach demonstrates the ability for CID 
approaches to operate on a timescale of minutes, generally CID based methods range from minutes 
to hours, limited by the requirement for efficient uptake of the chemical inducer, and are consequently 
not among the fastest acting tools for temporal control of protein dynamics. 
 
Light-induced dimerisation (LID) 
Another way in which protein dimerisation can be induced is via light-based methods, which take 
advantage of naturally occurring photosensitive protein domains that dimerise upon exposure to a 
certain wavelength of light (Fig. 1C, Table 1). Whilst maintaining the flexibility of CID approaches in 
terms of the response elicited and the many ways in which protein function can be disrupted, light-
based methods generally overcome many of the limitations of CID. In particular, they provide 
improved spatiotemporal precision, mitigate the requirement for exogenous small molecule addition 
and operate on a timescale of seconds. Genetically-encoded light-based (optogenetic) approaches 
have vastly expanded within the last decade from just a few applications to a whole toolbox of 
techniques with which to control protein activity [32]. Like CID, the first methods involving LID took 
advantage of naturally occurring photosensitive proteins, often discovered initially in plants, known as 
phytochromes and cryptochromes.  
 
Phytochromes 
Phytochromes are photoreceptive pigments encoded by small multigene families in plants and 
bacteria where they monitor red/far-red wavelengths of light [33, 34]. The most thoroughly 
investigated phytochromes are those from Arabidopsis thaliana, which normally function to modulate 
seed germination and shade avoidance [35]. One such protein is phytochrome B (PhyB) which 
undergoes a conformational change upon exposure to light of visible red wavelengths (~650-670 nm) 
to heterodimerise with the transcription factor phytochrome interaction factor 3 (PIP3). Unlike other 
photosensitive proteins, this dimerisation can be reverted through exposure to longer wavelengths of 
light (~700-750 nm), which induces monoisomerisation of PhyB and releases PIP3, allowing for very 
precise control of protein activity [32, 36].   
 
Cryptochromes 
Also commonly found in plants, Cryptochromes (Cry) are plant photosensors that absorb blue light, 
the most well studied of which, Cry2, heterodimerises with the cryptochrome-interacting basic-helix-
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loop-helix 1 (CIB1) transcription factor. Cryptochrome proteins have a C-terminal domain required for 
signal transduction and, like phytochromes, require a flavin adenine dinucleotide chromophore co-
factor, which binds to an N-terminal DNA photolyase homology region (PHR) [37, 38]. Since the 
discovery of Cyr2 and its ability to heterodimerise with CIB1, this system has been adapted to 
circumvent the need for exogenous chromophore addition [37]. With this improved system, Kennedy 
and colleagues [37] induced dimerisation of Cry2-CIB1 on a sub-millisecond timescale (in under 300 
µs), although the reverse process took minutes to complete. Nevertheless, this improved system has 
since been used in the study of a number of different cellular processes in model organisms. One 
field in which the Cry2-CIB1 system has been used successfully both in vitro [39] and in vivo [40] is 
the study of phosphoinositide signalling. This was achieved by Cry2-CIB1 mediated recruitment of a 
phosphoinositide phosphatase catalytic subunit responsible for the conversion of PI(4,5)P2 into 
phosphatidylinositol-4-phosphate (PI(4)P) to the plasma membrane in a light-dependent manner. 
Using this approach, Guglielmi et al [40] were able to study complex morphological changes and 
interactions that occur within defined timescales during Drosophila embryogenesis. The recruitment 
of the catalytic subunit to the plasma membrane within seconds of blue-light illumination was 
sufficient for quick depletion of PI(4,5)P2 which, given the role of phosphoinositides in regulating actin 
polymerisation, allowed control over cell contractility and facilitated the study of cell-cell interactions, 
force transmission and changes in tissue geometry [40].   
 
The use of cryptochromes for conditional dimerisation has since spawned a host of methods utilising 
the interaction between Cry2 and binding partners such as CIB1. One such method, known as light-
activated reversible inhibition by assembled trap (LARIAT), utilises light-mediated heterodimerisation 
to reversibly sequester target proteins into multimeric complexes in mammalian cells, by engineered 
interactions with multimeric proteins (Fig. 1D, Table 1) [41]. Lee and colleagues developed the 
LARIAT technique by fusing Ca2+/calmodulin-dependent protein kinase II (CaMKII) protein, which 
self-assembles into a 12 subunit oligomer, to CIB1. Upon blue light stimulation, CIB1 interacts with 
Cry2 and forms clusters through interconnections between CIB1-conjugated CaMKII multimeric 
proteins. Through this method of optogenetic trapping, Lee et al. [41] were able to induce cluster 
formation with high spatiotemporal precision in HeLa cells within 30 seconds upon illumination, with 
cluster disassembly occurring within minutes of light withdrawal. Lee and colleagues also found that 
the extent of clustering was correlated with the intensity or number of light pulses administered, 
suggesting it may be possible to quantitatively control clustering simply by varying light conditions for 
more intricate control of protein dynamics. This approach can also be used to inactivate GFP-tagged 
proteins, without the need to add an additional protein tag, through the use of anti-GFP nanobodies 
[41]. To demonstrate this approach, Lee et al. trapped a number of different GFP-tagged proteins into 
complexes through interactions with a CIB1-conjugated anti-GFP nanobody to acutely disrupt 
proteins involved in fast-acting processes such as membrane retention and spindle formation.  
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A recent example that displays the potential of the LARIAT approach is its application to the study of 
intracellular membrane trafficking. Here, Nguyen and colleagues [42] developed a system whereby 
intracellular membranes can be rapidly and reversibly sequestered into complexes via Cry2-induced 
aggregation of CIB1-conjugated GTPases. Using diverse Rab GTPases as membrane markers, it 
was possible to access specific intracellular membrane compartments such as the golgi and 
endoplasmic reticulum [42]. This approach makes it possible to dissect the spatiotemporal functions 
of intracellular membranes in a variety of processes such as receptor transport, intracellular 
signalling from endosomes, protein sorting and secretion. 
 
It is also known that many plant photosensors, including Cry2, are capable of forming aggregates 
upon light stimulation [43, 44]. For example, Wend and colleagues [45] demonstrated the ability of 
Cry2 to dimerise C-Raf and activate its kinase activity in a light-inducible manner, functionally 
separating C-Raf from upstream growth factor signalling, enabling a more controlled approach to 
study dynamic downstream effects on target protein phosphorylation and cell signalling. Interestingly 
Wend and colleagues also tested the ability of C-Raf-Cry2 to dimerise with CIB1-bound C-Raf and 
found a weaker activation of C-Raf, which they suggest may be due to a difference in stoichiometry 
when the larger Cry2 molecule binds to the much smaller CIB1 domain [45]. Another use of Cry2 
dimerisation is in a technique called Clustering Indirectly using Cryptochrome 2 (CLICR), which 
involves the clustering of transmembrane receptors to activate signal transduction (Fig. 2). This is 
achieved by indirect clustering of Cry2 bound to a receptor-binding domain (BD); high local 
concentrations of the BD then serve to cluster endogenous receptors leading to signal activation [46]. 
An N-terminal src-homology 2 (SH2) domain, which binds tyrosine-receptor kinases and the 
phosphotyrosine-binding-like F3 domain from Talin, which binds β3-integrin were shown to be 
effective BDs [46], suggesting the method could be modified to target a wide range of 
transmembrane proteins. However, the selectivity of such tools need to be empirically validated for 
each system. 
 
Light-oxygen-voltage domains 
An alternative approach to light-induced dimerisation involves the use of light-oxygen-voltage 
domains (LOV) from avena sativa phototropin 1 (Table 1). LOV domains contain a C-terminal -helix 
(J helix) which, upon light illumination and excitation of a flavin cofactor within the LOV domain, 
undergoes a large conformational change and unwinds [47]. This light-induced, structural change 
allows for the control of protein activity through allosteric regulation of proteins containing these LOV 
domains (Fig. 1E). One example of how LOV domains have aided the study of protein function is the 
application to the study of cell motility [48, 49]. Wu et al [48] fused Rac1 to a LOV domain, which, in 
its native -helix state, blocked Rac1 interactions. This photoactivatable Rac1 (PA-Rac1) could then 
be reversibly and repeatedly activated in precise cellular locations by illumination with blue-light, 
producing localised cell ruffling and protrusions. Localised Rac1 activation was also able to promote  
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directed cell motility [48]. PA-Rac analogues have since been used in further in vivo cell migration 
studies, showing for instance that Rac activation is sufficient for polarisation of the border cells in 
Drosophila oogenesis and that the directionality of the subsequent migration of these cells during egg 
chamber development is dependent on Rac levels [50]. Whist PA-Rac has been used successfully in 
a number of studies, the shift between the wound and unwound J helix states upon illumination is 
less than ideal, with at best a ten-fold shift towards the unfolded state upon light irradiation [51]. 
Through the identification of mutations that stabilise both the wound and unwound J helix states, 
Strickland et al., modified the LOV system and reduced the proportion of unwound J helix in the 
dark state to make the switch between light and dark states more defined and increase the dynamic 
range of the system as a whole, with up to a 70-fold shift in J helix state after exposure to light [52]. 
 
One example that takes advantage of the high spatial and temporal precision that can be achieved 
using LOV domains is the control of receptor tyrosine kinase (RTK) activation. RTKs are a family of 
cell surface receptors that respond to growth factor and hormone signals to regulate a variety of cell 
behaviours, and have previously proven difficult to study due to the rapid rates of receptor 
biosynthesis and degradation that can occur. Grusch and colleagues [53] used LOV-domain 
mediated dimerisation of mutant RTKs, insensitive to endogenous ligands, to induce  
transphosphorylation and therefore receptor activation on a timescale shorter than that of receptor 
synthesis/degradation. Through this approach they were able to mimic the cell behaviours induced by 
endogenous growth factors to provide control over cell signalling on the minute timescale, with 
diverse cellular responses in different cell types pointing to the involvement of different adapter 
proteins or feedback mechanisms [54].  
 
Light-based methods for induced protein complex formation and control of protein activity offer a 
powerful solution to many of the drawbacks that come with chemical-based approaches whilst 
maintaining versatility. Although light-based methods require laser excitation to stimulate photo-
activatable protein modules, the wavelengths of light used generally fall within the same range as 
those used for conventional fluorescence imaging, meaning cytotoxic effects are minimal and these 
approaches have therefore been applied successfully to both in vivo and in vitro studies [55]. The 
benefits of optogenetic approaches over the more traditional, well-studied small molecule 
approaches suggest that with further development, these tools will be invaluable in the use of 
complex formation for protein inactivation or sequestration in the study of fast-acting cellular 
processes.  
 
Protein Cleavage/Splicing 
Another common strategy for the inducible control of protein activity is to induce physical changes in 
protein sequence through the endogenous process of protein cleavage or splicing. As with methods 
for inducible protein complex formation, protein cleavage/splicing can be engineered to allow 
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induction via a number of different mechanisms including both small molecule based and light-based 
approaches (Fig. 3, Table 2). However, the mechanisms used to induce protein cleavage/splicing are 
often interchangeable, allowing these methods to be adapted to a wider range of systems and 
biological questions. 
 
Intein-mediated protein splicing 
One method that allows inducible control of protein activity uses the endogenous post-translational 
mechanism known as intein-mediated protein splicing (Table 2). With this method, intervening 
polypeptides known as inteins are used to catalyse their own removal from the flanking polypeptides, 
or exteins, which are subsequently joined back together. Inteins are typically removed in a four-step 
process involving conversion of the peptide bond linking the N-terminal extein to an ester or thioester 
bond and transfer of the N-extein to the C-extein by transesterification. The resulting branched ester 
is then resolved by asparagine cyclization followed by conversion of the newly formed ester bond 
linking the two exteins into an amide bond and hydrolysis of the C-terminal aminosuccinimide of the 
excised intein [56, 57]. Inteins are used in biotechnology for a number of different applications, 
including the control of protein expression or modification, post-translational processing and also 
protein labelling [57], but perhaps the most valuable application in terms of studying protein function 
is to facilitate the control of protein activity. Since inteins are extensively reviewed elsewhere [57-59] 
we will not discuss their use further here, except to say that they have been engineered to allow 
conditional protein splicing (CPS), such that the splicing process is induced by the activation of an 
intein through reduction or the addition of a trigger such as light, temperature, pH or the addition of a 
small molecule (Fig. 3A) [57, 60]. These systems have been used successfully both in cultured cells 
and in living animals to interrogate protein function, although they have not been widely adopted for 
this purpose perhaps because of their intrinsic lack of reversibility.  
 
TEV cleavage 
One common method for inducible protein cleavage as a mechanism to control protein activity 
exploits the ability of the tobacco etch virus (TEV) protease to cleave a highly specific seven amino 
acid recognition sequence (E-X-X-Y-X-Q-G/S) with high efficiency (Fig. 3B, Table 2) [61-63]. TEV is 
commonly used as a mechanism for the cleavage of fusion proteins to remove protein affinity tags 
prior to further protein analysis [64]; however, this system has also been applied to the control of 
protein activity both in vivo and in vitro. Through genetic modification, the TEV recognition sequence 
can be engineered into a protein of interest to allow inducible protein cleavage and inactivation when 
in the presence of TEV. TEV techniques have previously been demonstrated in budding yeast to 
provide evidence of a role for separin in anaphase initiation [65] and has since been applied to the 
study of proteins in both Drosophila cell culture and live embryos [66, 67]. For example, to show that 
TEV was able to effectively and specifically cleave a protein containing the recognition sequence in 
live Drosophila embryos, Harder et al [66] expressed the protein Megatrachea (Mega), a Drosophila 
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claudin protein localised to membrane compartments of ectodermal cells, containing an artificial TEV 
protease cleavage site (TEVpcs) and yellow fluorescent protein (YFP) (Mega-TEVpcs -YFP). Upon TEV 
expression using the Gal4/UAS system, Mega-TEVpcs-YFP no longer showed the correct YFP 
localisation indicating the YFP had been cleaved from the Mega fusion protein. Harder et al went on 
to adapt this system to allow induction of TEV expression at different stages of embryo development 
by putting TEV under the control of the heat-shock promoter 70 (hsp70), thus generating a 
mechanism for the temporal control of TEV-mediated protein cleavage. Using this temporally 
controlled system, they were then able to induce cleavage of a Mega-TEVpcs construct leading to 
truncation of the Mega protein and subsequent degradation of the truncated protein [66]. Clearly, a 
key factor in determining the timescale of TEV-mediated cleavage is the promoter from which TEV is 
expressed. Changes in temperature using the heat shock promoter, is capable of inducing TEV 
expression and protein cleavage in Drosophila pupae ~3 hours after a 45 minute heat shock [67], 
whereas rapamycin-induced expression in mammalian cells induces cleavage within 150 minutes 
[68]. This may make the approach unsuitable for the study of some processes that operate on a short 
timescale. 
 
One disadvantage of TEV is that it readily cleaves itself at a specific site to yield a truncated enzyme 
with greatly reduced activity [69, 70]. There have therefore been a number of iterative changes made 
to TEV protease to adapt the protease for more diverse applications, for example a TEV mutant has 
recently been designed specifically to be active in the secretory pathway [71]; various other TEV 
mutants offer the same recognition site cleavage, but an increased stability and reduced auto-
cleavage activity [69]. Whilst TEV offers highly specific and efficient cleavage, a priori knowledge 
about protein composition is required to choose a position where the TEV recognition site can 
tolerably be inserted that will inactivate the target protein whilst reducing the possibility that the 
resulting protein fragments will retain function or even have novel functions of their own. There is also 
an optimum level of TEV protease expression at which cleavage occurs but background activity is 
minimalised; this level is likely to depend on both the variation of TEV protease and the system in 
which it is applied so would need to be considered during experimental design [68]. 
 
The timescales and spatiotemporal resolution of both intein-mediated protein splicing and TEV 
cleavage are dependent on the engineered mechanism of induction. Whilst the ability to customise 
these techniques allows them to be applied to a wide range of systems and cellular processes, the 
fastest acting methods of protein cleavage/splicing with the highest spatiotemporal resolution are 
again those induced by light. 
 
CALI/FALI 
One method for light-inducible protein cleavage applied to the study of protein function is 
chromophore-assisted light inactivation (CALI), Table 2. Chromophores are photosensitive groups, 
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often responsible for the colour of organic molecules, which produce highly reactive free radicals 
such as reactive oxygen species (ROS) upon illumination with a specific wavelength of light. Using 
the CALI approach, a chromophore-tagged protein of interest is inactivated through mild illumination 
for a period of time sufficient to induce generation of reactive oxygen species and induce protein 
cleavage of proximate proteins, but short enough to ensure the reactive oxygen species act within a 
defined radius (30-40 Å) to minimise off target effects (Fig. 3C) [72]. The specificity of CALI 
approaches is determined by the short half-life of the free radical species, which ensures that only 
proteins within a radius of 1.5-6 nm relative to the chromophore are affected [72-74]. After free 
radical generation, proteins are typically inactivated within 1 second, which, combined with laser 
irradiation of micrometer accuracies, allows for high spatial resolution and highly controlled protein 
inactivation [74].  
 
Originally, CALI approaches used an antibody-based mechanism to attach a chromophore, such as 
the dye malachite green, to a protein of interest (Fig. 3C). Fluorophores such as fluorescin 
isothiocyanate, which are more efficient at ROS production, were later employed in a similar 
approach called fluorophore-assisted light inactivation (FALI) [75]. However, the need for 
microinjection of a dye-labelled, non-function blocking antibody specific to the protein of interest 
limited the widespread application of these approaches. Subsequent methods made use of genetic 
modification to label proteins with a generic tag that can then be fluorescently-labelled through 
extracellular addition of a specific reagent (Fig. 3C). Proteins tagged with 1-2 small tetracysteine (TC) 
motifs will specifically bind to the membrane permeable biarsenical dye resorufin-based arsenical 
hairpin binder (ReAsH) or the fluorescein-based arsenical hairpin binder (FlAsH). For example, 
Marek and colleagues [76] used FlAsH labelling to visualise Synaptotagmin I (Syt I) at the 
neuromuscular junction (NMJ) in late stage, live Drosophila larvae. Through photo-inactivation they 
were able to inactivate Syt I within seconds and provide supporting evidence for a model, previously 
based on genetic data alone, in which Syt I plays a role post-vesicle docking to mediate vesicle-
fusion and calcium-dependent transmitter release [76].  
 
Whilst dyes are added extracellularly in ReAsH/FlAsH based CALI/FALI approaches, the application 
of these techniques in vivo is limited by the difficult task of achieving sufficient uptake in live animals 
and also the inability to spatially control the production of ROS and limit it to particular cells or sub-
cellular compartments [77]. There is also the problem of non-specific binding of the membrane-
permeable dyes. For CALI/FALI to become a more widely used technique there was therefore a need 
for a system that sidestepped the requirement for exogenous addition and could be encoded 
completely through genetic manipulation. There has been some limited success using eGFP, a tag 
commonly used to study protein localisation and function. For example, CALI illumination of GFP-
myosin II was shown to result in unequal-size daughter cells during asymmetric cell divisions in a C. 
elegans Q neuroblast cell lineage [78]. It is however believed that the chromophore within the GFP 
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structure is protected by the outer shell meaning the generation of free-radical species upon 
illumination is restricted and therefore GFP holds a low phototoxicity [77, 79].  
 
KillerRed 
The first example of a successful genetically-encoded CALI reagent, with a 1,000-fold increase in 
phototoxicity compared to GFP, is the GFP-related red fluorescent protein KillerRed, developed from 
the nonfluorescent red chromoprotein anm2CP of Hydrozoa jellyfish (Fig. 3C) [79]. Whilst it was 
originally unclear why there was such an improvement in phototoxicity, a study into the structure-
function relationship of killerRed by Pletnev and colleagues provided crystallographic data revealing 
unique structural features that may facilitate ROS generation [80]. KillerRed has been used in a 
number of applications in biological research, such as the control of protein activity in the study of 
neuronal development in model organisms [81] and has been used to induce cell specific killing of 
eukaryotic cells in culture via mitochondrial or membrane-targeted KillerRed [79]. In this regard 
KillerRed has also proven to have uses in medicine; one recent and exciting application of KillerRed 
was to the experimental cancer treatment known as photodynamic therapy (PDT), which aims to use 
photosensitisers to selectively kill tumour cells through reactive oxygen species generation upon 
laser illumination [53, 82]. Following subcutaneaous injection of KillerRed expressing Escherichia coli 
(KR-E.coli) into mouse xenograft models of human carcinoma cell lines the Terekawa lab [82] 
monitored the intensity and spread of fluorescence through the tumour cells. After 24 hours the KR-
E.coli spread throughout the whole tumour and were subsequently irradiated with orange light (540-
580 nm) to induce ROS production. The generation of ROS led to necrosis and tumours gradually 
disappeared to leave healed skin after just 1 week demonstrating the ability of KR-E.coli to kill cancer 
cells originating from humans. Whilst there are many questions still to be answered before this 
technique is applicable to humans, these results provide an insight into the capabilities of genetically-
encoded CALI approaches. 
 
KillerRed has proven to be an exciting solution to the difficulties associated with previous CALI 
approaches. However, one limitation is its tendency to homodimerise, which can potentially interfere 
with protein function [77, 79]. There have been a number of other novel photosensitisers discovered 
since, such as SuperNova, a monomeric form of KillerRed [83], and the fluorescent flavoprotein mini 
Singlet Oxygen Generator (miniSOG), which can also be used to generate an insoluble deposit of 
singlet oxygen species that can be stained for visualisation using electron microscopy [84]. More 
recently, the toolkit of phototoxic proteins was expanded further with the addition of KillerOrange, an 
orange mutant version of KillerRed that results in ROS formation upon illumination with either blue or 
green light, meaning it can be used in combination with KillerRed or other photosensitisers activated 
by different wavelengths of light [85].  
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CALI/FALI approaches enable specific protein inactivation through phototoxicity and can act with high 
spatial resolution through the ability to express tagged proteins in specific cells and trigger 
inactivation at a sub-cellular level (Table 2). The expansion of the phototoxic protein toolbox should 
also allow for the creation of more intricately controlled systems in which different proteins can be 
inactivated at different timepoints or in different cell populations, which will form a useful tool both for 
fundamental research and for potential medical applications. However, CALI/FALI-based methods 
suffer from a number of limitations, including the requirement for either exogenous ligand addition or 
the inclusion of a fairly large protein tag that may interfere with protein function. Importantly, there is 
also potential for off-target effects on proteins in close vicinity to the ROS generator, challenging the 
specificity of these approaches. For example Guo and colleagues [86] found that the inhibition of 
calcium ion currents, mediated by the class C G-protein coupled receptor (GPCR) mGluR8a, was 
greatly attenuated following FALI inactivation. Whilst initial results were consistent with acute 
inactivation of mGluR8a, Guo and colleagues also reported collateral damage to proximal proteins 
with no overt link to pathways of GPCR signalling [86]. These factors have limited the adoption of 
such methods to study protein function and cannot be overlooked when using techniques involving 
phototoxicity for protein inactivation. 
 
Protein Stability/Degradation 
Whilst protein cleavage or splicing can often lead indirectly to protein instability and degradation, it is 
likely that this will occur after some delay depending on the half-life of the protein. It is also possible 
for the resulting protein fragments to retain function or bind other proteins and perform independent 
functions of their own, potentially generating a more severe phenotype than simple protein knockout 
alone. It therefore follows that a more thorough and interpretable approach for complete removal of 
proteins from cells is to target them directly for degradation by the endogenous cellular degradation 
pathways (Fig. 4, Table 3). Although the direct degradation of target proteins means these methods 
are technically irreversible and somewhat limited in their application, in most cases protein levels 
return to normal following relief of the degradation stimulus and thus these methods can still provide 
a useful tool for studying protein function [9, 10, 87]. Methods for inducible protein degradation 
generally involve the proteasome pathway for protein degradation, in which ubiquitin is transferred 
from the E1 ubiquitin-activating enzyme to the E2 ubiquitin-conjugating enzyme and subsequently to 
a lysine residue within the target protein in a transfer facilitated by the E3 ubiquitin ligase [88]. This 
process is repeated to polyubiquitinate the target protein until it has a sufficient number of ubiquitin 
molecules for targeted degradation by the proteasome [88]. 
 
N-end Degron 
A common strategy for the direct induction of protein degradation utilises the UBR1 E3 ligase 
pathway and the N-end rule (Table 3), which states that the half-life of a protein is determined by 
both the accessibility of lysine residues, for ubiquitination, and the identity of the amino acid at the N-
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terminus [89, 90]. Varshavsky and colleagues [90] demonstrated this principle through cleavage of 
ubiquitin, via a yeast deubiquitinating protease, from a fusion protein expressed in yeast, containing 
the 5’ end of a lacI linker followed by -galactosidase (-gal), resulting in the exposure of a new N-
terminal amino acid. The half-life of -gal following cleavage could then be vastly altered by simply 
changing the exposed amino acid residue. For example, -gal with an N-terminal Arginine or 
Phenylalanine residue had a half-life of ~3 minutes, whereas Methionine or Valine resulted in a half-
life greater than 20 hours [89]. This method of degradation is conserved from bacteria to higher 
eukaryotes, and means proteins tagged with the unstable lacI degron can be targeted for degradation 
within minutes [90]. However, this strategy is not inherently inducible and therefore requires 
modification for the conditional control of protein degradation. 
 
One of the first examples of an inducible N-end degron involved the use of a temperature sensitive 
dihydrofolate reductase variant (tsDHFR) where an N-terminal destabilising arginine was only 
exposed at non-permissive temperatures [91]. By fusing the tsDHFR to the N-terminus of a target 
protein, degradation can be induced by a switch to the non-permissive temperature of 35°C, 
exposing the N-terminus at which point the N-end rule takes effect (Fig. 4A). For example, this 
system has been used successfully in Drosophila, to inducibly polyubiquitinate an eGFP reporter 
protein at the neuromuscular synapse following a 30-minute heat shock at 35°C, in order to track the 
degradation of polyubiquitinated proteins [92]. By tracking the degradation of the eGFP, Speese and 
colleagues [92] showed that ubiquitinated presynaptic proteins are not removed from the synaptic 
terminal but rather undergo local proteasome-mediated degradation at pre-synaptic sites. In addition 
to examples from Drosophila, this technique has also been used successfully to characterise many 
essential proteins in budding yeast [93]. However, such techniques are generally limited to systems 
that can survive the required temperature changes and also to proteins that retain function with the 
required N-terminal modification. Despite this, the approach has since been used successfully in 
chicken DT40 cells, in which the method was first tested using a tsDHFR degron fused to eGFP. 
Upon transfer of the cells to the non-permissive temperature of 42°C, the protein was rapidly 
depleted to ~10% of initial levels within 90 minutes leading to undetectable levels after 120 minutes 
[94]. Moving cells back to the permissive temperature of 35°C resulted in an efficient recovery to the 
pre-depletion level within 150 minutes. Su and colleagues [94] then used the approach to deplete 
RAD51, finding that RAD51, which plays an important role in homologous DNA recombination (HDR), 
does not stop DNA synthesis but causes cell cycle arrest in G2, suggesting HDR becomes important 
at G2. This, along with the many other applications of tsDHFR-based approaches, show that whilst 
this method is limited in its potential applications, tsDHFR can still provide a useful tool in the study of 
protein function. 
 
In addition to a temperature-sensitive DHFR variant, a small molecule-controlled version has also 
been engineered, for which the drug methotrexate (MTX) regulates stability of the N-terminus. Whilst 
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the presence of MTX fails to inhibit recognition and therefore polyubiquitination of tsDHFR by E3 
ligase, the stable, high-affinity interaction between MTX and DHFR impedes protein unfolding and 
prevents degradation by the proteasome [95, 96]. This system was demonstrated in both yeast and 
mammalian cells in culture, although the occupancy of the proteome by the MTX-tsDHFR complex is 
likely to inhibit degradation of other cellular proteins leading to off-target effects [97]. Also, DHFR is 
required for the production of tetrahydrofolate, which is subsequently required for the synthesis of 
purines, thymidylate and several amino acids [98]. The inhibition of DHFR by MTX therefore 
interferes with the synthesis of DNA, RNA and even proteins, meaning MTX is undesirable as a 
regulatory small molecule for exogenous addition.  
 
TIPI (TEV protease mediated induction of protein instability) 
An alternative way in which the N-end degron system can be made inducible, and more widely 
applicable, is through the use of TEV in a technique called TEV protease-mediated induction of 
protein instability (TIPI), Table 3. This technique combines TEV with the N-end rule, whereby TEV 
cleaves a recognition sequence engineered into a cryptic N-degron, attached to the N-terminus of a 
target protein, to reveal an unstable N-end amino acid (Fig. 4B) [99]. According to the N-end rule, this 
unstable amino acid targets the protein for polyubiquitination and degradation via the UBR1 E3 ligase 
pathway [89, 90]. TEV protease has previously been shown to allow degeneracy within its recognition 
sequence and is particularly flexible to changes at position 7, the amino acid residue that forms the 
N-end following TEV cleavage [63]. TEV protease can therefore cope with the incorporation of an 
amino acid that induces degradation following cleavage via the N-end rule. Taxis et al [99] first 
developed the TIPI approach by designing a construct containing a reporter followed by a TEV 
protease recognition site, N-degron and SF3b155381-424 termed Reporter-TDegX-tag, where X 
represents the amino acid at position 7 which becomes the new N-terminal amino acid upon 
cleavage. The inclusion of a relatively short SF3b155381-424 domain allowed for more efficient 
cleavage as its binding to a mutant version of the human spliceosome subunit 14 (p14*) recruited 
p14*-TEV to the recognition site (Fig. 4B). Taxis and colleagues initially demonstrated this system in 
yeast using a GFP-TDegX-Don1p fusion protein, with p14*-TEV expression driven by the Gal1 
promoter, monitoring cleavage via the release of GFP and testing the effect of the amino acid at 
position X on TEV-cleavage efficiency and protein half-life. Phenylalanine or asparagine were found 
to provide optimal conditions for both TEV cleavage and rapid degradation of the target protein, 
Don1p. The effectiveness of TIPI was shown by using the approach to deplete several different 
proteins in yeast, obtaining phenotypes correlating to those observed via genetic knockdowns [99]. 
 
The potential of TIPI as an approach for conditional degradation is yet to be realised, however its 
power and versatility has recently been demonstrated in some alternative applications. For instance, 
TIPI has been further modified (mTIPI) to facilitate production of recombinant proteins; it does this by 
blocking endocytosis in yeast and combating a common problem whereby highly active endocytosis 
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in protein expression systems reduces the overall protein yield [100]. For conditional control this 
method simply requires expression of the p14*-TEV fusion protein, which could be induced via the 
same methods as for TEV cleavage, including temperature, pH, small molecule addition or the 
Gal4/UAS system, making it a versatile tool for inducible degradation and the study of protein 
function both in vivo and in vitro. 
 
Auxin-induced degron (AID)  
Another way in which proteins can be directly targeted for degradation by the ubiquitin-proteasome 
machinery is via F-box proteins, which bind target proteins and recruit the Cullin-RING complex, also 
called the SCF complex consisting of Skp1, Cullin and F-box, to ubiquitinate the target protein [101]. 
Eukaryotes contain multiple forms of SCF, whereby the F-box protein conveys specificity towards 
different target proteins. One F-box particularly suited to small molecule-induced control of protein 
degradation is the transport inhibitor response 1 (TIR1) protein, which binds target proteins in the 
presence of the plant hormone auxin and has a highly conserved interaction with the E3 ligase 
protein Skp1 (Fig. 4C) [102, 103]. This is commonly referred to as an auxin-inducible degron (AID) 
system (Table 3), and was initially shown to be applicable to most eukaryotes (excluding plants), 
including budding yeast and cell lines derived from human, mouse, hamster, monkey and chicken 
[104]. The AID degron consists of IAA17, also known as AXR3, from Arabidopsis thaliana and when 
expressed at either the C- or N-terminus of GFP in budding yeast also expressing AtTIR1, under the 
control of the galactose-inducible GAL promoter, the SCF-TIR1 complex was able to assemble and 
degrade GFP to less than 3% of initial levels within 30 minutes of auxin addition [104]. This approach 
was successfully used to degrade several essential nuclear or cytoplasmic proteins in yeast. 
However, to apply the system to mammalian cells it was first necessary to modify TIR1 to convey a 
higher thermostability and allow use at 37°C. This was achieved by sourcing TIR1 from the rice plant 
Oryza sativa (osTIR1), which also provided an improvement over atTIR1 for use in yeast [104].  
 
This method has since been used successfully to degrade both nuclear and cytoplasmic proteins in 
C.elegans [105] and  mammalian cells [106] to help identify the function of several different target 
proteins at specific time points of the cell cycle. Holland and colleagues [106] tested five differentially 
localised proteins, some of which were known to be incorporated into protein complexes. Four out of 
the five AID-YFP tagged proteins expressed under doxycline control (Plk4, CENP-A, TFR2 and cyclin 
B1), showed quantitative protein degradation within 80 minutes of auxin addition. Degradation of the 
other protein studied, H2B, occurred more slowly within 3 hours [106]. These results show that AID is 
capable of rapidly depleting proteins involved in stable complexes with relatively long half-lives, 
however, the time taken for depletion following induction can vary. Holland and colleagues 
demonstrated the ability of AID to induce proteolysis with the same or very similar degradation 
kinetics at all phases of the cell cycle and also found that proteins re-appeared almost immediately 
upon removal of auxin stimulus. To demonstrate the ability of AID to study protein function, Holland 
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and colleagues [106] achieved rapid functional inactivation of BubR1, an essential component of the 
mitotic checkpoint, by depleting endogenous BubR1 protein with siRNA, replacing it with siRNA-
resistant GFP-AID-BubR1 and inducing mitotic arrest through nocodazole addition. GFP-AID-BubR1 
rescued the function of the depleted endogenous BubR1 and this rescue could be rapidly reverted 
through auxin-induced degradation of the GFP-AID-BubR1 fusion protein to produce a more 
complete null phenotype than mRNA depletion alone [106]. 
 
The AID approach has since been developed further to increase versatility through minimisation of 
the degron size and the inclusion of a series of epitope tags to allow detection using fluorescence 
microscopy or commercially-available antibodies [107]. Morawska and colleagues [107] developed a 
series of vectors for PCR-based genomic tagging strategies containing different iterations of the AID 
degron with epitope tag, allowing for both C- or N-terminal tagging and providing a range of selection 
markers which they then demonstrated through application to a series of different yeast proteins. 
Whilst these vectors increase the versatility and facilitate use of the AID approach, individual proteins 
must still be considered on a case by case basis to design the most effective degron; it may even be 
necessary to test multiple iterations to ensure proteins retain function.  
 
PROTACS 
Another chemical-based method for the specific degradation of target proteins by the endogenous 
ubiquitin-proteasome machinery is through the use of heterobifunctional small molecules known as 
Proteolysis Targeting Chimeras (PROTACs), Table 3. PROTACs consist of one moiety that binds the 
target protein linked to an E3 ligase to directly recruit the protein for proteasome-mediated 
degradation. Initially developed to target disease-causing proteins for destruction, the first generation 
of PROTACs were based on large peptide motifs derived from known ubiquitin ligase substrates 
[108]. However, these were limited by high molecular weight, poor cellular uptake and potential 
metabolic instability [109, 110]. Following a switch to small molecule-based PROTACs, the past 
decade has seen a series of improvements to PROTAC technology, aided by the development of 
small ligands for a number of E3 ligases, including MDM2, clAP1, CRBN and VHL (as reviewed by 
[110]). Whist these improved small molecule PROTACs were able to successfully degrade target 
proteins, the overall uptake of this technique for the conditional control of protein degradation has 
been limited by a number of uncertainties, including PROTAC stability and E3 ligase binding affinity 
[109, 110]. However, more recent advances in the field have provided a new generation of highly 
specific, high affinity, low molecular weight PROTACs with the potential to expand the use of 
PROTAC technology [111-114].  
 
For example, Bondeson and colleagues [111] used structure-guided approaches to develop low 
molecular weight (~450 Da), high affinity ligands for the Cullin-RING ligase 2 VHL E3 complex 
(CRL2VHL). Linked to small molecules that bind specific cellular targets, Bondeson and colleagues 
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were able to efficiently degrade specific proteins in cultured cell lines, including the serine-threonine 
kinase RIPK2, which is involved in innate immune signalling, and the estrogen-related receptor alpha 
(ERR), which is implicated in the regulation of various cellular metabolism pathways, with dose 
dependent degradation and maximal degradation levels of >95% and 86%, respectively. Bondeson 
and colleagues also demonstrated this approach in vivo using a PROTAC targeting ERR,  reducing 
its levels by ~50% and significantly reducing mouse heart and kidney tumours by >40% [111]. Using 
a similar approach, Zengerle and colleagues [114] successfully designed potent PROTACs using 
optimised, drug-like VHL ligands [115] and BET bromodomain protein ligands to selectively degrade 
certain members of the Bromo- and Extra-terminal (BET) protein family, including the epigenetic 
regulator BRD4 previously identified as a potential therapeutic target for acute myeloid leukaemia 
and ovarian cancer [114]. 
 
In addition to targeting proteins to the CRL2VHL E3 complex, potent PROTACs have also been 
developed to utilise the interaction between immunomodulatory drugs (IMiDs), such as thalidomide, 
and the CRL4CRBN E3 ligase. CRL4CRBN, together with an IMiD, forms a tertiary complex with the 
transcription factor Ikaros, resulting in its ubiquitination and degradation. This approach has since 
been used for the efficient and specific degradation of BRD2, BRD3 and BRD4 by attaching BET 
bromodomain protein ligands to an IMiD [112, 113].  
 
Whilst the principle behind PROTAC technology is not novel, there has been a recent surge of 
developments to generate a newer generation of more potent PROTACs, which address the 
limitations of previous iterations. These newer PROTACs offer greatly increased potency whilst 
retaining high specificity to their target proteins both in vitro and in vivo. It is also possible to modify 
this specificity through manipulation of the linker between the two PROTAC moieties [111, 114]. The 
diversity of recently described examples shows how the PROTAC approach can work on different 
protein targets in a number of different systems. However, compared with small molecules used in 
other approaches to conditionally control protein dynamics, PROTACS are larger and more complex 
molecules and so may suffer limitations with respect to their pharmacokinetic properties. 
 
deGradFP 
The F-box/SCF complex-based approach has also been utilised in the deGradFP method to 
specifically degrade GFP-tagged fusion proteins via an anti-GFP nanobody/F-box chimera (Fig. 4D, 
Table 3). A method to allow specific degradation of proteins tagged with GFP is desirable as GFP 
tagged constructs already exist for many proteins and degradation can be easily monitored by the 
loss of fluorescence. The degrade GFP (deGradFP) method involves the engineered F-box fusion 
protein NSlmb-vhhGFP4, consisting of an F-box domain derived from the Drosophila protein Slmb 
and the single-domain anti-GFP antibody fragment vhhGFP4 which recognises GFP and its close 
derivatives (Fig. 4D) [116]. This method was initially demonstrated in Drosophila, where, with NSlmb-
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vhhGFP4 expression restricted to the posterior of early stage embryos by the Gal4/UAS system, an 
EYFP tagged histone H2A variant (His2Av-EYFP) was rapidly depleted by the deGradFP system 
[116]. Caussinus and colleagues used the engrailed-Gal4 driver to express both NSlmb-vhhGFP4 
and nuclear mCherry in embryos ubiquitously expressing His2Av-EYFP. Using mCherry levels as a 
reporter for the expression of NSlmb-vhhGFP4, His2Av-EYFP started to be degraded after ~30 
minutes following NSlmb-vhhGFP4 expression, with less than 10% of the maximum EGFP intensity 
remaining after ~ 3 hours [116]. Caussinus and colleagues then went on to show the versatility of the 
deGradFP approach through the successful depletion of the cytoplasmic protein Spaghetti squash 
(Sqh), nuclear protein Apterous (Ap) and the transmembrane protein Crumbs (Crb) all of which were 
tagged with GFP, expressed in a null background and degraded upon induction of NSlmb-vhhGFP4 
expression via the Gal4/UAS system. There were, however, a couple of cases in which the 
deGradFP was not effective against GFP-tagged target proteins. For example, E-Cadherin/Shotgun 
(Shg) could not be degraded using this method, possibly as it exists in a large protein complex which 
may mean the GFP tag is not accessible to the vhhGFP4 antibody [116]. Also, NSlmb-vhhGFP4 was 
unable to induce degradation of GFP alone, perhaps as the small size of GFP prevents exposure to 
the SCF-recruited E2 enzyme and thus prevents poly-ubiquitination. It was however possible to 
degrade GFP containing a small nuclear localisation signal via this method, so whilst it is possible 
that a minimum size limit exists, below which degradation does not occur, this limit must be very 
close to the size of GFP alone and should not greatly limit the versatility of the approach [116]. 
 
deGradFP has been proven to be a useful approach for the induced degradation of target proteins 
particularly in combination with RNAi knockdowns in order to generate a more effective depletion of 
protein levels [117, 118]. More recently, a similar approach involving the modification of the E3 
ubiquitin ligase adapter protein SPOP to alter target protein specificity was proposed [119]. By fusing 
an anti-GFP nanobody directly to a truncated SPOP adapter protein completely lacking its substrate-
binding domain, Schin and colleagues [119] claim to have developed an approach that is more 
efficient than deGradFP, which simply involves an NSlmb deletion mutant for which the binding 
domain has been modified. This remains to be proven in terms of biological applications, but may 
offer an alternative in cases where deGradFP is not effective. deGradFP, and related methods, can 
in theory be adapted to allow knockdown of many endogenous proteins, providing high-affinity 
antibodies are available for target proteins [87]. 
 
Ubiquitin-independent 
Ubiquitin-mediated protein degradation is by far the most common strategy for control of protein 
degradation, however it has previously been shown that localisation to the proteasome is sufficient 
for degradation [120] and so it is worth mentioning here that there are also a handful of methods for 
the conditional control of ubiquitin-independent protein degradation. The most common of these is 
the C-degron; consisting of a 36 amino acid sequence from Ornithine decarboxylase (ODC) this 
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forms a bridged association to the proteasome, acting as both the recognition and degradation 
initiation signal [87]. An exciting use of this technique allows for light-induced protein degradation via 
the use of LOV2 domains [121]. Renicke and colleagues designed a system in which the C-degron, 
fused to the C-terminus of the LOV domain, can be masked by the J-helix under dark conditions, 
but exposed upon illumination with blue-light via J-helix unfolding, leading to ubiquitin-independent 
protein degradation. Whilst this provides an exciting alternative, ubiquitin-dependent methods remain 
the most widely used and well-studied methods for inducible protein degradation. 
 
Concluding comments and future perspectives 
Manipulation of genes, at the level of DNA or RNA, has proven to be a specific and immensely 
powerful way of understanding the roles of encoded proteins in their native cellular environment. 
However, distinguishing between the initial and steady-state consequences of gene disruption, 
especially in vivo, is often problematic. The new generation of tools and methods that are emerging 
to meet this challenge address the issue by offering both rapid and specific control of protein 
function. Different sets of tools can be employed across a range of time scales to challenge biological 
processes operating at the subcellular, cellular and multicellular level. Methods for conditional control 
of protein complex formation (Table 1), in particular, open the door to in vivo analysis of biochemical 
processes operating over short times (sec/min), such as intracellular signaling cascades, which are 
initiated within seconds of receiving the stimulus. Furthermore, the ability to reversibly switch 
activities on and off enables the systematic perturbation of biochemical pathways, thereby revealing 
how information is processed from upstream stimulus to downstream effectors at each step and 
providing insights into rate limiting components and feedback control [122]. Repetitive perturbation at 
different times has particular value in the dissection of biological systems where frequency variation, 
including oscillatory behaviours, encodes information [123, 124]. Other techniques, including those 
that conditionally control protein splicing/cleavage or degradation, typically operate over min-h 
timescales (see Tables 2-3) but have proven utility in studying the molecular mechanisms of 
downstream events, such as changes in cell proliferation, differentiation, migration or adhesion, 
which operate over longer times.  
 
It is important to note, as discussed in the sections above, that current methodologies for conditional 
perturbation of protein function are not without their technical limitations and researchers must weigh 
up whether the available tools offer the appropriate flexibility and precision for the desired 
experiment. One of the main considerations for researchers wishing to utilise the methods we have 
described is to decide which inducer they should use. Chemically-induced methods have been the 
mainstay of the field for many years, but the use of chemical inducers is often restricted because of 
their promiscuous binding profiles, which can lead to off-target effects and cytotoxicity. As we have 
discussed, higher affinity ligands might mitigate these effects, because the compounds can be used 
at lower concentrations, typically suffer from not being reversible. More fundamentally however, the 
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inability to target some chemicals to specific subcellular localisations, combined with their relatively 
slow uptake in cells, with effects occurring in minutes to hours, make these methods unsuitable for 
the study of certain biological processes and in vivo models. 
 
Recently, there has been a surge of activity to develop methods of induction using light. One of the 
key attractions of this approach is that perturbations can be both rapid and reversible, in a spatially-
resolved manner. Consequently, with light-dependent systems, even should an activated protein 
diffuse out of the area in which it received the activating input, it will then switch off, preventing 
phenotypic outputs from losing their spatial resolution [55]. Correspondingly, there has been a great 
deal of focus on improving the properties of the light-sensitive domains used in these approaches, 
much in the same way that there have been iterative improvements made to fluorescent proteins for 
use in cell imaging. This will make it possible to tailor the perturbation dynamics. For instance, in the 
case of light-induced complex formation, a derivative of the Cry2 domain (Cry2-olig) with altered off 
kinetics may make it more suitable for sequestration and inhibition of protein activity [125]. A 
challenge to future efforts for improvement to such domains will be not just to identify variants that 
confer beneficial properties in isolation, but ones that retain additive effects of multiple genetic 
changes; this will require screening procedures that simultaneously optimise constructs against 
multiple parameters.  
 
The ultimate goal of the approaches we have described is to understand the role of molecules in 
biological phenomena with quantitative precision. Quantitative in vivo biochemistry however, requires 
measurement not just of the effects of perturbation on a given process, but also the magnitude of the 
perturbation to the target protein in time and space. Whilst reliable molecular readouts might be 
available for the former, the latter may be somewhat harder to measure. Fluorescently-labelled target 
proteins offer an attractive solution for methods relying on protein degradation, since fluorescence 
intensity can provide a measure of protein concentration with spatiotemporal resolution [126]. 
However, whilst quantitation of other perturbations, e.g. protein cleavage or activation, may be 
straightforward in cell populations at fixed time points, measurements with single cell resolution or in 
real time will be much more challenging to achieve. A number of advanced cell imaging approaches 
may make this possible, but these techniques are themselves technically demanding and may not be 
widely available to researchers who do not have access to specialised equipment. For instance, 
measurements of protein dynamics (e.g. with Fluorescence cross-correlation spectroscopy, or Raster 
image correlation spectroscopy)  and protein proximity (e.g. with Förster resonance energy transfer - 
FRET, and Fluorescence-lifetime imaging) can be employed to determine effects on protein complex 
formation [127], whilst specialist (e.g. FRET-based) reporters can measure e.g. the activity of 
enzymes responsible for post-translational modifications [128]. Future developments will therefore 
have to consider appropriate strategies, not just to perturb protein function, but to simultaneously 
measure the extent of that perturbation along with the biological effect(s).  
23 
 
 
Concurrently, an ongoing challenge for technology developers is to make the techniques universally 
appealing and easy to employ. Ultimately, whether a technique is proven to be robust and fit for 
purpose will depend on uptake and testing by user communities. From a practical perspective, it may 
still take a significant investment of time to tailor an approach to the experimental system under 
investigation, despite efforts to make the available tools universally applicable. Prior knowledge of 
protein structure/function relationships may be required, for example, to guide the production of 
fusion proteins that retain normal activity and respond effectively to regulatory stimuli. These issues 
have inevitably limited the uptake of many of these techniques. Methods that utilise tools that are 
already widely-employed, such as GFP-tagged proteins, are likely to be amongst the most popular in 
the short-term because the methodologies can be rapidly deployed. For instance, deGradFP will no 
doubt be of particular interest to the Drosophila and zebrafish communities, which are creating 
transgenic libraries in which endogenous genes have been tagged with GFP [129, 130]. Indeed, such 
collections may be the starting point for well-designed, temporally-controlled screens, to identify 
novel genes involved in developmentally-regulated biological processes.  
  
As the field continues to mature, an area of future development is likely to be how multiple 
techniques might be combined for improved spatiotemporal control of a single protein, or for the 
induction of more than one protein, which has application in the engineering and study of artificial 
networks. Importantly, conditional control of protein function is not exclusive of genetic manipulation. 
Ultimately therefore, as gene-editing “knock-in” strategies mature [131], it may become routine to 
incorporate any number of different conditional domains on a genome-wide scale to facilitate such 
studies. 
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Figure 1. Schematic representation of methods for the control of protein activity by induced 
complex formation. Methods described here can be broadly categorised by their method of 
induction. (A) Generalised mechanism for small-molecule mediated approaches involving small 
molecule, chemical inducers of dimerisation (CID) to sequester protein activity by promoting 
(dis)aggregation, altering transcription or by changing the sub-cellular localisation of target proteins. 
(B) A specific example of this approach is illustrated by the Knocksideways method, which involves 
the rapid sequestration of target proteins to the mitochondria through rapamycin mediated interaction 
between the FKBP tagged target protein and the mitochondrially localised mito-RFP-FRB trap. (C) 
The generalised mechanism for light-based approaches induced by exposure to a specific 
wavelength of light. More specific examples of light-based methods are also illustrated in D-E. (D) 
Schematic of the light-activated reversible inhibition by assembled trap (LARIAT) method, whereby 
target proteins tagged with CRY2 are sequestered into large protein complexes upon a light-induced 
conformational change to produce the photoactivated form of CRY2. This interacts with CIB1-bound 
multimeric complexes to aggregate the target protein and sequester activity. (E) Representation of 
LOV-domain-based approaches, which involve a light-induced conformational change leading to 
unravelling of the j-helix and the loss of its interaction with the LOV domain leaving the target 
protein free to bind interactors and perform its function. 
 
Figure 2. Clustering Indirectly Using Cryptochrome 2 (CLICR). In the dark, un-induced state, 
monomers of Cry2 fused to a receptor targeting binding domain (BD) (Cry2-BD) exist in an 
unclustered state and therefore have a weak affinity for the target receptor. Upon blue light 
stimulation, Cry2-BD molecules oligomerise, increasing the local concentration of BD and conferring 
a high avidity for the target receptor. These oligomers undergo membrane translocation and cluster 
target transmembrane receptors. 
 
Figure 3. Illustration of methods for conditional protein splicing or protein cleavage to 
(in)activate target proteins. (A) Illustration of conditional protein cis-splicing induced by activation of 
an intein through a change in redox state or via a trigger, which may be addition of a small molecule, 
as depicted here, a change in pH, temperature or irradiation with a specific wavelength of light. 
Protein trans-splicing is also possible, whereby dimerisation domains can be used to reassociate split 
intein fragments upon addition of a trigger. (B) Illustration of TEV protease mediated cleavage of a 
TEV recognition site engineered within a protein of interest leading to protein inactivation upon 
induction of TEV protease expression. (C) Schematic representation of chromophore/fluorophore-
assisted light inactivation (CALI/FALI) induced by addition of a dye conjugated ligand or antibody, or 
via genetically-encoded methods involving photosensitisers such as KillerRed, eGFP, miniSOG or 
SuperNova. Upon irradiation with a specific wavelength of light these produce reactive oxygen 
species (1O2) leading to inactivation of proteins in the immediate vicinity. 
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Figure 4. Illustration of methods for inducible protein degradation divided into those involving 
the N-end rule or F-box based pathways (A) N-end degron method, involving the exposure of an 
unstable N-terminal amino acid which can be induced by a number of mechanisms including 
temperature or small molecule based mechanisms. This unstable end is subsequently targeted for 
polyubiquitination by an E3 ligase, such as Ubr1P in yeast, and degraded via the proteasome 
pathway. (B) TEV protease mediated induction of protein instability (TIPI) which utilises TEV 
protease mediated cleavage of a seven amino acid TEV recognition site to reveal an unstable N-
terminal amino acid, subsequently targeted for proteasome mediated degradation as for the N-end 
degron approach. The efficiency of TEV cleavage is increased by the inclusion of a short SF3b155381-
424 domain downstream of the TEV recognition site, which binds to a mutant version of the human 
spliceosome subunit 14 (p14*) bringing p14*-TEV to the recognition site. (C) Illustration of the 
mechanism for auxin-induced degradation of target proteins tagged with an auxin-inducible degron 
(AID). Upon addition of auxin, the AID tagged protein is recruited to an engineered E3 ubiquitin ligase 
SCF complex, containing the transport inhibitor response 1 (TIR1) F-box protein from plants, which 
binds target proteins in the presence of the plant hormone auxin. Expressing TIR1 in non-plant cells 
is enough to result in formation of the SCF complex which then binds AID tagged proteins in an 
auxin-dependent manner, leading to poly-ubiquitination and degradation via the proteasome. (D) 
Schematic of the deGradFP method for inducible protein degradation. The GFP tagged target protein 
is recruited to an engineered SCF complex containing the F-box protein NSlmb conjugated to an anti-
GFP single chain antibody (vhhGFP4). Target protein is polyubiquitinated via the recruited E2 
ubiquitin ligase and subsequently degraded via the endogenous proteasome machinery. 
 
 
Table 1. Summary of methods for conditional control of protein complex formation 
  
Technique Protein 
Disruption 
Timescal
e 
Can be induced by … 
Small molecule 
/hormone 
Light Temperature pH 
Chemically induced 
dimerisation (CID) 
Sequestration/
(in)activation 
min/h  
e.g. FK1012, 
Rapamycin 
   
Knocksideways (KS) Sequestration min  
Rapamycin 
   
Light-activated 
dimerisation 
Sequestration/
(In)activation 
sec/min   
 
  
Light-Activated 
Reversible Inhibition 
by Assembled Trap 
(LARIAT) 
 
(In)activation sec   
Blue light: 
450-495 nm 
  
Light-Oxygen-Voltage 
(LOV) domains 
(In)activation sec/min   
Blue light: 
450-495 nm 
  
 
 
Table 2. Summary of methods for conditional control of protein splicing/cleavage 
  
Technique Protein 
Disruption 
Timescale Can be induced by … 
Small molecule 
/hormone 
Light Temperature pH 
 Intein mediated 
protein splicing 
Inactivation via 
protein splicing 
h  
 
 
 
 
 
 
 
Tobacco Etch 
Virus (TEV)-
protease 
cleavage 
 
Inactivation via 
protein cleavage 
min 
 
Promoter dependent 
 
Chromophore-
Assisted Light 
Inactivation 
(CALI) 
Inactivation by 
ROS 
Often 
<1 sec 
  
e.g. 
Malachite 
green: 616- 
624 nm 
KillerRed: 
540-580 nm 
 
  
Fluorophore-
Assisted Light 
Inactivation 
(FALI) 
Inactivation by 
ROS 
<10 min   
e.g. Fluorescin 
isothiocyanate 
493-518 nm 
  
 
 
Table 3. Summary of methods for conditional control of protein degradation 
 
Technique Protein 
Disruption 
Timescale Can be induced by … 
Small molecule 
/hormone 
Light Temperature pH 
N-end Degron Unstable N-
end amino 
acid 
ubiquitination 
min-h, 
sometimes 
<30 min 
 
e.g. Methotrexate 
  
e.g. 37-42°C 
 
 
TEV protease 
mediated induction 
of protein 
instability (TIPI) 
Unstable N-
end amino 
acid 
ubiquitination 
min/h Promoter dependent 
Auxin-induced 
degradation (AID) 
F-box induced 
ubiquitination 
<30 min  
Auxin 
   
Proteolysis 
Targeting Chimeras 
(PROTACS) 
Direct 
targeting to E3 
ligase 
complexes 
 
min/h  
PROTAC 
   
deGradFP F-box induced 
ubiquitination 
min/h Promoter dependent 
 




